Snowflake Score | |
---|---|
Valuation | 6/6 |
Future Growth | 3/6 |
Past Performance | 2/6 |
Financial Health | 5/6 |
Dividends | 4/6 |
SHWG.F Stock Overview
Shandong Weigao Group Medical Polymer Company Limited engages in the research and development, production, and sale of single-use medical devices in the People’s Republic of China.
Shandong Weigao Group Medical Polymer Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | HK$1.07 |
52 Week High | HK$2.58 |
52 Week Low | HK$1.07 |
Beta | 0.51 |
1 Month Change | -1.39% |
3 Month Change | n/a |
1 Year Change | n/a |
3 Year Change | 22.41% |
5 Year Change | n/a |
Change since IPO | -56.88% |
Recent News & Updates
Shareholder Returns
SHWG.F | US Medical Equipment | US Market | |
---|---|---|---|
7D | 0% | -10.7% | -10.1% |
1Y | n/a | -17.5% | -10.8% |
Return vs Industry: Insufficient data to determine how SHWG.F performed against the US Medical Equipment industry.
Return vs Market: Insufficient data to determine how SHWG.F performed against the US Market.
Price Volatility
SHWG.F volatility | |
---|---|
SHWG.F Average Weekly Movement | n/a |
Medical Equipment Industry Average Movement | 9.7% |
Market Average Movement | 7.7% |
10% most volatile stocks in US Market | 16.4% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: Insufficient data to determine SHWG.F's volatility over the past 3 months.
Volatility Over Time: Insufficient data to determine SHWG.F's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2000 | 11,123 | Rinan Cong | https://www.weigaogroup.com |
Shandong Weigao Group Medical Polymer Company Limited engages in the research and development, production, and sale of single-use medical devices in the People’s Republic of China. It operates through Medical Device Products, Orthopaedic Products, Interventional Products, Pharma Packaging Products, Blood Management Products, and Others segments. The company offers vascular and non-vascular access infusion devices, infusion sets, syringes, puncture needles, and specialized single-use clinical collection kits; wound sutures, wound healing dressings, and wound cleaning and nonvascular catheter supporting extracorporeal devices; and blood collection, storage, separation, and sterilization equipment.
Shandong Weigao Group Medical Polymer Fundamentals Summary
SHWG.F fundamental statistics | |
---|---|
Market Cap | CN¥30.24b |
Earnings (TTM) | CN¥2.24b |
Revenue (TTM) | CN¥13.15b |
13.5x
P/E Ratio2.3x
P/S RatioIs SHWG.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
SHWG.F income statement (TTM) | |
---|---|
Revenue | CN¥13.15b |
Cost of Revenue | CN¥5.90b |
Gross Profit | CN¥7.25b |
Other Expenses | CN¥5.01b |
Earnings | CN¥2.24b |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
n/a
Earnings per share (EPS) | 0.49 |
Gross Margin | 55.14% |
Net Profit Margin | 17.07% |
Debt/Equity Ratio | 19.4% |
How did SHWG.F perform over the long term?
See historical performance and comparisonDividends
2.1%
Current Dividend Yield28%
Payout RatioValuation
Is Shandong Weigao Group Medical Polymer undervalued compared to its fair value and its price relative to the market?
Valuation Score
6/6Valuation Score 6/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry
26.1%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: SHWG.F ($1.07) is trading below our estimate of fair value ($1.44)
Significantly Below Fair Value: SHWG.F is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: SHWG.F is good value based on its PE Ratio (13.5x) compared to the US Medical Equipment industry average (32.7x).
PE vs Market: SHWG.F is good value based on its PE Ratio (13.5x) compared to the US market (15.3x).
Price to Earnings Growth Ratio
PEG Ratio: SHWG.F is good value based on its PEG Ratio (0.9x)
Price to Book Ratio
PB vs Industry: SHWG.F is good value based on its PB Ratio (1.6x) compared to the US Medical Equipment industry average (2.4x).
Future Growth
How is Shandong Weigao Group Medical Polymer forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
Future Growth Score
3/6Future Growth Score 3/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
14.9%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SHWG.F's forecast earnings growth (14.9% per year) is above the savings rate (1.9%).
Earnings vs Market: SHWG.F's earnings (14.9% per year) are forecast to grow faster than the US market (12.3% per year).
High Growth Earnings: SHWG.F's earnings are forecast to grow, but not significantly.
Revenue vs Market: SHWG.F's revenue (13% per year) is forecast to grow faster than the US market (7.8% per year).
High Growth Revenue: SHWG.F's revenue (13% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SHWG.F's Return on Equity is forecast to be low in 3 years time (11.7%).
Past Performance
How has Shandong Weigao Group Medical Polymer performed over the past 5 years?
Past Performance Score
2/6Past Performance Score 2/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
15.0%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SHWG.F has high quality earnings.
Growing Profit Margin: SHWG.F's current net profit margins (17.1%) are lower than last year (18%).
Past Earnings Growth Analysis
Earnings Trend: SHWG.F's earnings have grown by 15% per year over the past 5 years.
Accelerating Growth: SHWG.F's earnings growth over the past year (7.6%) is below its 5-year average (15% per year).
Earnings vs Industry: SHWG.F earnings growth over the past year (7.6%) underperformed the Medical Equipment industry 19.1%.
Return on Equity
High ROE: SHWG.F's Return on Equity (11.6%) is considered low.
Financial Health
How is Shandong Weigao Group Medical Polymer's financial position?
Financial Health Score
5/6Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage
Financial Position Analysis
Short Term Liabilities: SHWG.F's short term assets (CN¥16.1B) exceed its short term liabilities (CN¥5.1B).
Long Term Liabilities: SHWG.F's short term assets (CN¥16.1B) exceed its long term liabilities (CN¥4.3B).
Debt to Equity History and Analysis
Debt Level: SHWG.F has more cash than its total debt.
Reducing Debt: SHWG.F's debt to equity ratio has increased from 9.8% to 19.4% over the past 5 years.
Debt Coverage: SHWG.F's debt is well covered by operating cash flow (74.8%).
Interest Coverage: SHWG.F earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Dividend
What is Shandong Weigao Group Medical Polymer current dividend yield, its reliability and sustainability?
Dividend Score
4/6Dividend Score 4/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
2.15%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: SHWG.F's dividend (2.15%) is higher than the bottom 25% of dividend payers in the US market (1.56%).
High Dividend: SHWG.F's dividend (2.15%) is low compared to the top 25% of dividend payers in the US market (4.08%).
Stability and Growth of Payments
Stable Dividend: SHWG.F's dividend payments have been volatile in the past 10 years.
Growing Dividend: SHWG.F's dividend payments have increased over the past 10 years.
Earnings Payout to Shareholders
Earnings Coverage: With its reasonably low payout ratio (28.5%), SHWG.F's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonably low cash payout ratio (33.8%), SHWG.F's dividend payments are well covered by cash flows.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
5.8yrs
Average management tenure
CEO
Rinan Cong (40 yo)
1.17yrs
Tenure
Mr. Rinan Cong serves as Chief Executive Officer at Shandong Weigao Group Medical Polymer Company Limited since March 30, 2021 and serves as Executive Director since May 24, 2021. He joined the Company in...
Leadership Team
Experienced Management: SHWG.F's management team is seasoned and experienced (5.8 years average tenure).
Board Members
Experienced Board: SHWG.F's board of directors are not considered experienced ( 1.2 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Shandong Weigao Group Medical Polymer Company Limited's employee growth, exchange listings and data sources
Key Information
- Name: Shandong Weigao Group Medical Polymer Company Limited
- Ticker: SHWG.F
- Exchange: OTCPK
- Founded: 2000
- Industry: Health Care Supplies
- Sector: Healthcare
- Implied Market Cap: HK$34.965b
- Listing Market Cap: HK$4.454b
- Shares outstanding: 4.57b
- Website: https://www.weigaogroup.com
Number of Employees
Location
- Shandong Weigao Group Medical Polymer Company Limited
- Torch Hi-Tech Science Park
- 18 Xingshan Road
- Weihai
- Shandong Province
- 264210
- China
Listings
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2022/05/13 00:00 |
End of Day Share Price | 2022/04/29 00:00 |
Earnings | 2021/12/31 |
Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.